This enzyme exhibits a 60-fold higher hydrolytic efficiency against irinotecan than CES1, another human carboxylesterase isozyme [1], and the ability of colorectal tumors to hydrolyze irinotecan correlates with their expression of CES2, but not CES1 [2]. The gene discussed is CES1; the disease is colorectal neoplasm.